<DOC>
	<DOCNO>NCT00004141</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . Combining one drug different type biological therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus biological therapy treat patient metastatic melanoma .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Biological Therapy Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity cisplatin dacarbazine follow sargramostim ( GM-CSF ) , interferon alfa , interleukin-2 patient metastatic melanoma . - Determine objective response rate , relapse free survival , overall survival patient regimen . OUTLINE : Patients receive cisplatin IV 1 hour dacarbazine IV 30-60 minute sequentially day 1 , follow sargramostim ( GM-CSF ) subcutaneously ( SC ) day 2-7 , interleukin-2 SC day 8-14 , interferon alfa SC day 8 , 10 , 12 , 14 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 8 week disease progression , every 8-12 week thereafter . PROJECTED ACCRUAL : A total 15-45 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma Stage III intransit metastasis Stage IV No uncontrolled brain metastasis CT scan No clinically significant ascites pleural effusion PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : At least 10 week Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.5 g/dL Hepatic : Bilirubin great 2.0 mg/dL SGOT great 4 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 70 mL/min Cardiovascular : No clinically significant cardiac disease EKG , echocardiogram , MUGA scan Pulmonary : No clinically significant pulmonary disease chest xray Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant thyroid dysfunction No concurrent severe infection No medical psychiatric condition would interfere compliance No second malignancy within past 5 year , except : Localized nonmelanomatous skin cancer Carcinoma situ cervix Grade 1 Ta bladder cancer Suspected hear deficit must undergo audiologic test PRIOR CONCURRENT THERAPY : Biologic therapy : No one prior immunotherapy regimen At least 4 week since prior immunotherapy Adjuvant interferon alfa relapse allow Chemotherapy : No one prior chemotherapy regimen At least 4 week since prior chemotherapy ( 6 week since nitrosoureas ) No concurrent cyclophosphamide No concurrent chemotherapy Endocrine therapy : No concurrent corticosteroid cyclosporine A Radiotherapy : At least 2 week since prior radiotherapy Surgery : At least 3 week since major surgery Other : No concurrent immunosuppressive drug No concurrent investigational antineoplastic drug Concurrent thyroid replacement therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>